Last reviewed · How we verify

ISV-305 — Competitive Intelligence Brief

ISV-305 (ISV-305) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

phase 3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ISV-305 (ISV-305) — Sun Pharmaceutical Industries Limited. ISV-305 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ISV-305 TARGET ISV-305 Sun Pharmaceutical Industries Limited phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ISV-305 — Competitive Intelligence Brief. https://druglandscape.com/ci/isv-305. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: